Key result
Abciximab bolus only demonstrated similar clinical efficacy to the standard bolus plus infusion protocol for dissolving newly formed thrombus, but reduced hospital stay and bleeding complications.
Why the study?
Does an abciximab bolus-only strategy provide similar efficacy for thrombus dissolution and better safety compared to a standard bolus-plus-infusion protocol for newly formed thrombus during coronary intervention?
Cohort (n=72)
Yes
Does an abciximab bolus-only strategy provide similar efficacy for thrombus dissolution and better safety compared to a standard bolus-plus-infusion protocol for newly formed thrombus during coronary intervention?
For newly formed thrombus during percutaneous coronary intervention, an abciximab bolus-only strategy appears as effective as the standard bolus-plus-infusion protocol for thrombus dissolution, but with fewer bleeding complications and shorter hospital stays.
Answers are grounded in this paper and cite their sources.
Bolus-only abciximab may reduce bleeding and stay in new PCI thrombus; leaves open randomized confirmation of efficacy equivalence.
The study observed the effect on thrombus of the glycoprotein IIb/IIIa antagonist abciximab. We studied retrospectively 72 patients, who had definite or possible thrombus that was newly developed during cardiac intervention.
No takes yet. Share an insight, caveat, or question.
GAO et al. (2022) conducted a cohort in Acute intra-coronary thrombosis during percutaneous coronary intervention (n=72). Abciximab bolus only vs. Standard abciximab protocol (0.25 mg/kg bolus + 12-hour infusion at 0.125 µg/min/kg) was evaluated on Hospital stay (days) (p=<0.05). Abciximab bolus only demonstrated similar clinical efficacy to the standard bolus plus infusion protocol for dissolving newly formed thrombus, but reduced hospital stay and bleeding complications.
Synapse has enriched 10 related papers. Consider them for comparative context: